Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Fineline Cube Apr 9, 2026
Company Drug

Changchun BCHT Gains NMPA Approval for BK-01 Adjuvanted Influenza Vaccine

Fineline Cube Jun 20, 2025

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) announced that it has received clinical trial...

Company Drug Policy / Regulatory

NMPA’s CDE Reports 4,900 Clinical Trial Filings for Innovative Drugs in 2024

Fineline Cube Jun 20, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released its...

Company Deals Drug

Beijing Science Sun Pharma Inks RMB20M Drug Tech Transfer Pact for NeoAB33 Project

Fineline Cube Jun 20, 2025

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a Drug Technology Transfer Agreement with...

Company Drug Policy / Regulatory

CDE Issues New Requirements for IND Applications of Innovative Drugs

Fineline Cube Jun 20, 2025

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) this week...

Company Deals

ADVANZ PHARMA Acquires Bayer’s Testoviron Commercial Rights in Key Markets

Fineline Cube Jun 20, 2025

UK-based ADVANZ PHARMA announced the acquisition of commercial rights to testoviron from German giant Bayer...

Company Deals

Medtide’s IPO Raises HKD 514 Million to Expand Global Peptide CRDMO Services

Fineline Cube Jun 20, 2025

Hangzhou-based Medtide Inc., a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides,...

Company Drug

Shanghai Innogen’s Diabetes Drug Patent for Efsubaglutide Alfa Fully Invalidated

Fineline Cube Jun 20, 2025

Shanghai Innogen Pharmaceutical Technology Co., Ltd recently had its patent for efsubaglutide alfa (brand name:...

Company Drug

Shandong Xinhua Pharma Initiates Phase II Study of OAB-14 for Alzheimer’s Disease

Fineline Cube Jun 20, 2025

China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) announced the initiation of a Phase II...

Company Medical Device

Bayer Wins Beijing MPA Approval for MEDRAD Stellant D-CE Medical Device

Fineline Cube Jun 20, 2025

German giant Bayer AG (ETR: BAYN) announced that it has received marketing approval from the...

Company Drug

Joincare Pharma Gets NMPA Green Light for Pediatric Influenza Drug JKN2301

Fineline Cube Jun 20, 2025

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that it has received clinical...

Company Deals

Abbott Partners with Abu Dhabi Department of Health to Localize Pharma Production and Digital Health Solutions

Fineline Cube Jun 20, 2025

US-based health care firm Abbott (NYSE: ABT) this week entered into a partnership with the...

Company Deals

Sanofi and Abu Dhabi Department of Health Collaborate to Accelerate Vaccine Development

Fineline Cube Jun 20, 2025

France major Sanofi (NASDAQ: SNY) this week signed a Memorandum of Understanding (MoU) with the...

Company Drug

Platinum Life Biotech’s Ruibosheng First Prescribed in China for aGVHD Treatment

Fineline Cube Jun 20, 2025

Beijing-based Platinum Life Biotech’s Ruibosheng (amimestrocel) has been first prescribed in China, following conditional marketing...

Company Drug

MindRank’s MDR-001 Phase IIb Study Achieves Clinical Endpoints for Weight Loss

Fineline Cube Jun 20, 2025

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd announced that the multi-center, 24-week Phase IIb...

Company Drug

Eccogene Announces First Patient Dosing in Phase Ib Study of AZD5004/ECC5004 in China

Fineline Cube Jun 19, 2025

Sino-US firm Eccogene Inc., a partner of UK major AstraZeneca (AZ, NASDAQ: AZN), announced the...

Company Drug

Simcere Zaiming Initiates US Phase I Study of SIM0500 for Relapsed/Refractory Multiple Myeloma

Fineline Cube Jun 19, 2025

China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary Simcere Zaiming announced the first patient dosing...

Drug Medical Device Policy / Regulatory

FDA Launches ‘Elsa’ AI Tool to Enhance Staff Efficiency in Regulatory Processes

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) announced the launch of an artificial intelligence (AI)...

Drug Policy / Regulatory

FDA Launches Immediate Review of Clinical Trials Involving Cell Transfer to Hostile Countries

Fineline Cube Jun 19, 2025

The U.S. Food and Drug Administration (FDA) this week announced an immediate review of new...

Company Drug

Gilead’s Yeztugo Approved by FDA as First Six-Monthly Injectable HIV PrEP

Fineline Cube Jun 19, 2025

US-based Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has received market approval from the...

Company Drug

Fosun Pharma’s Fumaining Launches Clinically for Rare Disease Treatment in China

Fineline Cube Jun 19, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd.’s (HKG: 2196, SHA: 600196) in-house developed Category 1 drug...

Posts pagination

1 … 122 123 124 … 647

Recent updates

  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
  • Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.